This is a fully human IgG1/kappa monoclonal antibody using the same sequences as the therapeutic antibody secukinumab. It specifically targets IL17A, a proinflammatory cytokine primarily produced by T helper 17 cells and implicated in various chronic immune-mediated inflammatory disorders, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. IL17A is frequently upregulated in multiple autoimmune disorders, and exhibits greater potency than IL17F, another member of IL17, with a high affinity to IL17R. Secukinumab selectively binds to and inhibits IL17A, to prevent its interaction with IL17R and subsequent activation of the associated signaling pathway.